| abstract |
Novel quinazoline and cinnoline derivatives having the formula <IMAGE> (I) (wherein one of A and B is CH and the other one of A and B is N; X1 is halogen or CF3 and X3 is one of the groups II, III, IV or V NR1QNR2R3 (II) <IMAGE> (III) <IMAGE> (IV) <IMAGE> (V) where Q is lower alkylene; R1 is hydrogen or lower alkyl; R2 and R3 are independently lower alkyl or R2 and R3 are a divalent radical such that HNR2R3 is a secondary cyclic amine with 5 to 7 ring atoms; R4 is lower alkyl; n is 0 or 1; the rings shown in formulae III and IV are piperidine or pyrrolidine optionally substituted by lower alkyl; and the ring shown in formula V is piperazine optionally substituted by lower alkyl) and their pharmaceutically acceptable salts are useful as pharmaceuticals particularly as anti-hypertensives. Novel intermediates are also described including the corresponding sulphonic acids of formula I (where A, B and X1 are defined above and X3 is OH). |